EGFR Uncommon Mutations trials recruiting in Pennsylvania

Fewer than 3 recruiting trials found.

All EGFR Uncommon Mutations trials nationally

Cities in Pennsylvania

Recruiting trials in Pennsylvania

• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
  NCT07185997 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia